HOME >> MEDICINE >> NEWS
Newly developed treatment for severe grief shown more effective than standard therapy

A recently developed method for treating complicated grief, which includes discussing certain aspects of the death of a loved one, was found more effective than a standard therapy for depression, according to a study in the June 1 issue of JAMA.

Many physicians are uncertain about how to identify bereaved individuals who need treatment, and what treatments work for bereavement-related mental health problems, according to background information in the article. Bereavement-related major depressive disorder (MDD) is a well-recognized consequence of loss. Complicated grief also occurs in the aftermath of loss but is different from depression. Key features of complicated grief, persisting more than 6 months after the death of a loved one, include (1) a sense of disbelief regarding the death; (2) anger and bitterness over the death; (3) recurrent pangs of painful emotions, with intense yearning and longing for the deceased; and (4) preoccupation with thoughts of the loved one, often including distressing intrusive thoughts related to the death.

Complicated grief is a source of significant distress and impairment and is associated with a range of negative health consequences, but the results of existing treatments for it have been disappointing. Prevalence rates are estimated at approximately 10 percent to 20 percent of bereaved persons. Approximately 2.5 million people die yearly in the United States. Estimates suggest each death leaves an average of 5 people bereaved, suggesting that more than 1 million people per year are expected to develop complicated grief in the United States.

Given observations regarding the specificity and clinical significance of complicated grief symptoms, including the lack of response to standard treatments for depression, the researchers developed a targeted complicated grief treatment (CGT). They modified standard interpersonal psychotherapy (IPT) for grief-related depression to include cognitive-behavioral th
'"/>

Contact: Lisa Rossi
412-647-3555
JAMA and Archives Journals
31-May-2005


Page: 1 2 3

Related medicine news :

1. Newly discovered behavior in cancer cells signals dangerous metastasis
2. Newly discovered killer cell fights cancer
3. Newly discovered gene may predict aggressive ovarian cancer
4. Newly published summer camp health guideline advises parents, camp directors
5. Newly discovered branding process helps immune system cells pick their fights
6. Clinical guidelines for blood conservation during cardiac procedures developed
7. Tequila raw ingredient being developed into drug-carrier that targets colon diseases
8. Probe to detect spread of breast cancer co-developed by UH scientist
9. Faster, more accurate tuberculosis test developed
10. Anthrax detector developed
11. Standard developed for collection of suspicious powders

Post Your Comments:
(Date:7/30/2015)... ... 30, 2015 , ... Zaca Life has created Recovery Chewable ... water needed, the refreshing berry-flavored tablets are the perfect travel companion. , “We ... that may help with body detoxification, protection and hydration,” said Mark Aleks, Zaca ...
(Date:7/30/2015)... ... July 30, 2015 , ... The American Telemedicine Association (ATA) ... Tradeshow focused exclusively on telemedicine, telehealth and mHealth. The meeting, expected to attract ... take place May 14-17, 2016 in Minneapolis, MN. , ATA’s annual meeting attracts ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Orange, Riverside, Los Angeles, and San Bernardino counties, today announced that Dr. Michael ... Care Administrator. Dr. Demoratz is a strong proponent of early access to palliative ...
(Date:7/30/2015)... ... 2015 , ... The Beryl Institute announces its sixth annual ... Patient Experience Institute, these offerings reinforce the commitment to help frame and expand ... the experience movement, and provide information and research to support expanded focus and ...
(Date:7/30/2015)... ... July 30, 2015 , ... The Mesothelioma Applied Research ... Patient Registry Act of 2015’. The bill was introduced in Congress yesterday by ... Betty McCollum (D-MN), Joe Kennedy (D-MA), and Leonard Lance (R-NJ). The purpose of ...
Breaking Medicine News(10 mins):Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 2Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 3Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 3Health News:Bill to Create Patient Registry for Deadly Cancer Introduced in Congress 2
(Date:7/29/2015)... July 30, 2015 Roche (SIX: RO, ROG; ... cobas® EGFR Mutation Test v2 for Premarket Approval ... (FDA), as a companion diagnostic test for AZD9291, ... cancer patients with an acquired resistant mutation.  ... who have adenocarcinoma with tumor containing an EGFR ...
(Date:7/29/2015)... 2015  Unilife Corporation ("Unilife" or the "Company") (NASDAQ: ... and supplier of injectable drug delivery systems, today announced ... the Company with flexibility and control to support its ... an equity purchase agreement for up to $45 million ... Chicago -based institutional investor, which provides the ...
(Date:7/29/2015)... BERKELEY, Calif. , July 29, 2015 /PRNewswire/ ... of the Daiichi Sankyo Group, announced today that ... clinical trial results demonstrating that the investigational drug, PLX3397, ... in most patients with tenosynovial giant cell tumor (TGCT), ... tendon sheath. Following phase 1 dose-escalation, which ...
Breaking Medicine Technology:Roche submits filing to FDA for companion diagnostic for non-small cell lung cancer drug therapy 2Roche submits filing to FDA for companion diagnostic for non-small cell lung cancer drug therapy 3Unilife Announces Multifaceted Financing Strategy 2Unilife Announces Multifaceted Financing Strategy 3Unilife Announces Multifaceted Financing Strategy 4Unilife Announces Multifaceted Financing Strategy 5Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 2Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 3Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 4Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 5
Cached News: